News & Events

Top 10 Questions to Ask Your Doctor About Your Malignant Mesothelioma Cancer Diagnosis

Malignant Mesothelioma can be confusing and devastating. Pronouncing “Mesothelioma” is a challenge, as is the disease. You are your best...

RS ONCOLOGY PRESENTS POSTERS AT INTERNATIONAL CONFERENCE

AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS - BOSTON, MA Our Chief Scientist, Brian Cunniff,...

RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of

New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of Aggressive Mesotheliomas, Improving Druggability Data...

RS Oncology Announces Completion of First-in-Human Phase 1 Clinical Trial of RSO-021, a Novel Irreve

Cambridge, Mass., Sept 12, 2023 – RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate...

RS Oncology presents new drug in early clinical development for Mesothelioma and lung cancer patient

Start-up US biotech company tackling rare diseases presents three case studies in France Lille, France (2023) RS Oncology is bringing...

AACR 2023, RSO-021, a first in class treatment

Florida, April 2023 Our Chief Science Officer, Dr. Brian Cunniff successfully presented key research at AACR 2023. Characterization of...

Mesothelioma UK

September 21, 2022 Mesothelioma Matters UK highlighted RS Oncology in their Autumn Newsletter. 15% of cancer patients develop pleural...

ESMO CONGRESS September 2022

We look forward to presenting at ESMO in September.

RS Oncology, LLC Announces Initiation of Patient Dosing in Phase 1/2 MITOPE Clinical Trial of RSO-2

4 April 2022, Cambridge, MA -- RS Oncology, LLC, (RSO) a biotechnical company focused on the treatment of patients with malignant pleural...

Subscribe to our newsletter • Don’t miss out!